The content on this site is intended for healthcare professionals only
Dr Garon speaks with ecancertv at the Best of ASCO 2016 about targetable mutations in lung cancer.
With examples of BRAF and RET mutations, he discusses the clinical significance of sequencing data in achieving a patient's best possible responses to therapy.
For more on lung cancer sequencing, watch Dr Bruce Johnson speaking to ecancertv at WIN 2016.
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in radiology Tanzania
Overview of the management of HER2-low breast cancer patients
Molecular profiling in prostate cancer: key challenges for clinical implementation
